IBRX Stock Analysis: Buy, Sell, or Hold?
IBRX - ImmunityBio, Inc. Common Stock
$6.05
0.41 (7.27%)
▲
5d:
-3.2%
30d:
+175.0%
90d:
+181.4%
BUY
MODERATE Confidence
Analysis Updated: Feb 6, 2026 12:00 AM ET
Earnings: Mar 02, 2026
20d
Smart Money Accumulation
IBRX is down 9.0% this week, but smart money is accumulating calls. Top strike: $3.5 2026-03-20 with 11,626 OI. Call ratio: 74% View Scanner →
Strength: 7.0/10
Get Alerted When IBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
107 traders called IBRX this week
90% bullish • 24 bearish
90% bullish • 24 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IBRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IBRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IBRX is currently trading at $6.05, which is considered slightly high relative to its 30-day fair value range of $2.49 to $6.41.
Technical Outlook: Technically, IBRX is in a downtrend. Immediate support is located at $5.54, while resistance sits at $6.75. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.80 (+95.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IBRX is in a downtrend. Immediate support is located at $5.54, while resistance sits at $6.75. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.80 (+95.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$2.49 -
$6.41
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.3%)
- BULLISH: Trading 95.0% below Wall St target ($11.80)
Fair Price Analysis
30-Day Fair Range
$2.49 -
$6.41
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$5.54
Resistance Level
$6.75
Current Trend
Downtrend
Technical data as of
Feb 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.57
Wall Street Target
$11.80
(+95.0%)
Revenue Growth (YoY)
425.1%
Share & Embed Analysis
Last updated: February 08, 2026 11:26 PM ET
Data refreshes hourly during market hours. Next update: 12:26 AM
Data refreshes hourly during market hours. Next update: 12:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Barry J Simon
SELL
151967 shares
2026-01-20
Christobel Selecky
SELL
25000 shares
2026-01-20
Christobel Selecky
SELL
50000 shares
2026-01-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1032 | 51 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$215 | 61 BUY |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
12 analysts |
$142 | 61 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 51 HOLD |
Advanced IBRX Option Strategies
Professional options setups generated by AI based on today's IBRX price and gamma walls.
